

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-36. (canceled)

37. (previously presented) A composition of matter comprising as an admixture at least one compound selected from group (i) and at least one compound selected from group (ii),

wherein group (i) consists of:

Group a) consisting of:


tramadol, O-demethyltramadol or O-demethyl-N-mono-demethyl-tramadol,

Group b) consisting of:

- codeine
- dextropropoxyphene
- dihydrocodeine
- diphenoxylate
- ethylmorphine
- meptazinol
- nalbuphine
- pethidine
- tilidine
- tramadol
- viminol
- butorphanol
- dextromoramide
- dezocine
- diacetylmorphine

- hydrocodone
- hydromorphone
- ketobemidone
- levomethadone
- levomethadyl-acetate-(1- $\alpha$ -acetylmethadol)
- levorphanol
- morphine
- nalorphine
- oxycodone
- pentazocine
- piritramide
- alfentanil
- buprenorphine
- etorphine
- fentanyl
- remifentanyl
- sufentanyl

Group c) consisting of: 1-phenyl-3-dimethylamino-propane compounds  
corresponding to formula I




wherein

X is OH, F, Cl, H or OC(O)R<sup>7</sup>, where R<sup>7</sup> is chosen from C<sub>1-3</sub>-alkyl,  
branched or unbranched, saturated or unsaturated,  
unsubstituted or mono- or polysubstituted,

R<sup>1</sup> is chosen from C<sub>1-4</sub>-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted,  
R<sup>2</sup> and R<sup>3</sup> in each case independently of one another are chosen from H or C<sub>1-4</sub>-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted, or  
R<sup>2</sup> and R<sup>3</sup> together form a saturated C<sub>4-7</sub>-cycloalkyl radical, unsubstituted or mono- or polysubstituted,  
R<sup>9</sup> to R<sup>13</sup> in each case independently of one another are chosen from H, F, Cl, Br, I, CH<sub>2</sub>F, CHF<sub>2</sub>, CF<sub>3</sub>, OH, SH, OR<sup>14</sup>, OCF<sub>3</sub>, SR<sup>14</sup>, NR<sup>17</sup>R<sup>18</sup>, SOCH<sub>3</sub>, SOCF<sub>3</sub>; SO<sub>2</sub>CH<sub>3</sub>, SO<sub>2</sub>CF<sub>3</sub>, CN, COOR<sup>14</sup>, NO<sub>2</sub>, CONR<sup>17</sup>R<sup>18</sup>; C<sub>1-6</sub>-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, unsubstituted or mono- or polysubstituted;  
where R<sup>14</sup> is chosen from C<sub>1-6</sub>-alkyl; pyridyl, thienyl, thiazolyl, phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted; PO(O-C<sub>1-4</sub>-alkyl)<sub>2</sub>, CO(OC<sub>1-5</sub>-alkyl), CONH-C<sub>6</sub>H<sub>4</sub>-(C<sub>1-3</sub>-alkyl), CO(C<sub>1-5</sub>-alkyl), CO-CHR<sup>17</sup>-NHR<sup>18</sup>, CO-C<sub>6</sub>H<sub>4</sub>-R<sup>15</sup>, where R<sup>15</sup> is ortho-OCOC<sub>1-3</sub>-alkyl or meta- or para-CH<sub>2</sub>N(R<sup>16</sup>)<sub>2</sub> where R<sup>16</sup> is C<sub>1-4</sub>-alkyl or 4-morpholino, wherein in the radicals R<sup>14</sup>, R<sup>15</sup> and R<sup>16</sup> the alkyl groups are branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted;  
where R<sup>17</sup> and R<sup>18</sup> in each case independently of one another are chosen from H; C<sub>1-6</sub>-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted, or  
R<sup>9</sup> and R<sup>10</sup> or R<sup>10</sup> and R<sup>11</sup> together form an OCH<sub>2</sub>O, OCH<sub>2</sub>CH<sub>2</sub>O, OCH=CH, CH=CHO, CH=C(CH<sub>3</sub>)O, OC(CH<sub>3</sub>)=CH, (CH<sub>2</sub>)<sub>4</sub> or OCH=CHO ring,

Group d) consisting of substituted 6-dimethylaminomethyl-1-phenylcyclohexane compounds corresponding to formula II



II

wherein

X is OH, F, Cl, H or OC(O)R<sup>7</sup>, where R<sup>7</sup> is chosen from C<sub>1-3</sub>-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted,

R<sup>1</sup> is C<sub>1-4</sub>-alkyl, benzyl, CF<sub>3</sub>, OH, OCH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>, O-C<sub>1-4</sub>-alkyl, Cl or F and


R<sup>9</sup> to R<sup>13</sup> in each case independently of one another are chosen from H, F, Cl, Br, I, CH<sub>2</sub>F, CHF<sub>2</sub>, CF<sub>3</sub>, OH, SH, OR<sup>14</sup>, OCF<sub>3</sub>, SR<sup>14</sup>, NR<sup>17</sup>R<sup>18</sup>, SOCH<sub>3</sub>, SOCF<sub>3</sub>; SO<sub>2</sub>CH<sub>3</sub>, SO<sub>2</sub>CF<sub>3</sub>, CN, COOR<sup>14</sup>, NO<sub>2</sub>, CONR<sup>17</sup>R<sup>18</sup>; C<sub>1-6</sub>-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, unsubstituted or mono- or polysubstituted;

where R<sup>14</sup> is chosen from C<sub>1-6</sub>-alkyl; pyridyl, thienyl, thiazolyl, phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted; PO(O-C<sub>1-4</sub>-alkyl)<sub>2</sub>, CO(OC<sub>1-5</sub>-alkyl), CONH-C<sub>6</sub>H<sub>4</sub>-(C<sub>1-3</sub>-alkyl), CO(C<sub>1-5</sub>-alkyl), CO-CHR<sup>17</sup>-NHR<sup>18</sup>, CO-C<sub>6</sub>H<sub>4</sub>-R<sup>15</sup>, where R<sup>15</sup> is ortho-OCOC<sub>1-3</sub>-alkyl or meta- or para-CH<sub>2</sub>N(R<sup>16</sup>)<sub>2</sub> where R<sup>16</sup> is C<sub>1-4</sub>-alkyl or 4-morpholino, wherein in the radicals R<sup>14</sup>, R<sup>15</sup> and R<sup>16</sup> the alkyl

groups are branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; where  $R^{17}$  and  $R^{18}$  in each case independently of one another are chosen from the group consisting of H;  $C_{1-6}$ -alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted, or

$R^9$  and  $R^{10}$  or  $R^{10}$  and  $R^{11}$  together form an  $OCH_2O$ ,  $OCH_2CH_2O$ ,  $OCH=CH$ ,  $CH=CHO$ ,  $CH=C(CH_3)O$ ,  $OC(CH_3)=CH$ ,  $(CH_2)_4$  or  $OCH=CHO$  ring,

Group e) consisting of 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds corresponding to formula III



III

wherein

X is OH, F, Cl, H or  $OC(O)R^7$ , where  $R^7$  is chosen from  $C_{1-3}$ -alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted, and

$R^9$  to  $R^{13}$  in each case independently of one another are chosen from H, F, Cl, Br, I,  $CH_2F$ ,  $CHF_2$ ,  $CF_3$ , OH, SH,  $OR^{14}$ ,  $OCF_3$ ,  $SR^{14}$ ,  $NR^{17}R^{18}$ ,  $SOCH_3$ ,  $SOCF_3$ ;  $SO_2CH_3$ ,  $SO_2CF_3$ , CN,  $COOR^{14}$ ,  $NO_2$ ,  $CONR^{17}R^{18}$ ;  $C_{1-6}$ -alkyl, branched or unbranched, saturated or

unsaturated, unsubstituted or mono- or polysubstituted; phenyl, unsubstituted or mono- or polysubstituted;

where R<sup>14</sup> is chosen from the group consisting of C<sub>1-6</sub>-alkyl; pyridyl, thienyl, thiazolyl, phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted; PO(O-C<sub>1-4</sub>-alkyl)<sub>2</sub>, CO(OC<sub>1-5</sub>-alkyl), CONH-C<sub>6</sub>H<sub>4</sub>-(C<sub>1-3</sub>-alkyl), CO(C<sub>1-5</sub>-alkyl), CO-CHR<sup>17</sup>-NHR<sup>18</sup>, CO-C<sub>6</sub>H<sub>4</sub>-R<sup>15</sup>, where R<sup>15</sup> is ortho-OCOC<sub>1-3</sub>-alkyl or meta- or para-CH<sub>2</sub>N(R<sup>16</sup>)<sub>2</sub> where R<sup>16</sup> is C<sub>1-4</sub>-alkyl or 4-morpholino, wherein in the radicals R<sup>14</sup>, R<sup>15</sup> and R<sup>16</sup> the alkyl groups are branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; where R<sup>17</sup> and R<sup>18</sup> in each case independently of one another are chosen from H; C<sub>1-6</sub>-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted, or

R<sup>9</sup> and R<sup>10</sup> or R<sup>10</sup> and R<sup>11</sup> together form an OCH<sub>2</sub>O, OCH<sub>2</sub>CH<sub>2</sub>O, OCH=CH, CH=CHO, CH=C(CH<sub>3</sub>)O, OC(CH<sub>3</sub>)=CH, (CH<sub>2</sub>)<sub>4</sub> or OCH=CHO ring,

with the proviso that if R<sup>9</sup>, R<sup>11</sup> and R<sup>13</sup> correspond to H and one of R<sup>10</sup> or R<sup>12</sup> corresponds to H and the other corresponds to OCH<sub>3</sub>, X may not be OH, and

wherein group (ii) consists of an anti-muscarine agent selected from the group consisting of atropine, oxybutinin, propiverine, propantheline, emepronium, trospium, tolterodine, darifenacin and  $\alpha,\alpha$ -diphenylacetic acid 4-(N-methylpiperidyl) ester, duloxetine, imipramine and desmopressin, or a salt of any of the foregoing with a physiologically tolerated acid.

38. (currently amended) The composition of matter of claim 37, wherein one or more of

said at least one compound selected from group (i) and  
said at least one compound selected from group (ii)  
is present in the form of a free base.

39. (currently amended) The composition of matter of claim 37, wherein one or more of

said at least one compound selected from group (i) and  
said at least one compound selected from group (ii)  
is present in the form of a pure enantiomer or pure diastereoisomer.

40. (currently amended) The composition of matter of claim 37, wherein one or more of

said at least one compound selected from group (i) and  
said at least one compound selected from group (ii)  
is present in the form of a mixture of stereoisomers.

41. (currently amended) The composition of matter of claim 40, wherein one or more of

said at least one compound selected from group (i) and  
said at least one compound selected from group (ii)  
is present in the form of a racemic mixture.

42-43. (canceled)

44. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group a) consisting of tramadol, (+)-O-demethyltramadol and (+)-O-demethyl-N-mono-demethyl-tramadol.

45. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is (+)-tramadol.

46. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group b) consisting of:

- codeine
- dextropropoxyphene
- dihydrocodeine
- diphenoxylate
- ethylmorphine
- meptazinol
- nalbuphine
- pethidine tilidine
- viminol
- butorphanol
- dezocine
- nalorphine
- pentazocine, and
- buprenorphine.

47. (previously presented) The composition of matter of claim 46, wherein said at least one compound selected from group (i) is selected from the group consisting of:

- codeine
- dextropropoxyphene
- dihydrocodeine
- meptazinol



- nalbuphine
- tilidine, and
- buprenorphine.

48. (currently amended) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein:

X is chosen from the group consisting of OH, F, Cl, OC(O)CH<sub>3</sub> and H,

R<sup>1</sup> is chosen from C<sub>1-4</sub>-alkyl, saturated and unsubstituted, branched or unbranched;

R<sup>2</sup> and R<sup>3</sup> independently of one another are chosen from the group consisting of H, and C<sub>1-4</sub>-alkyl, saturated and unsubstituted, branched or unbranched; or

R<sup>2</sup> and R<sup>3</sup> together form a C<sub>5-6</sub>-cycloalkyl radical, saturated or unsaturated, unsubstituted or mono- or polysubstituted,

R<sup>9</sup> to R<sup>13</sup> are independently chosen from the group consisting of H, Cl, F, OH, CF<sub>2</sub>H, CF<sub>3</sub> and C<sub>1-4</sub>-alkyl, saturated and unsubstituted, branched or unbranched; OR<sup>14</sup> or SR<sup>14</sup>, where R<sup>14</sup> is chosen from C<sub>1-3</sub>-alkyl, saturated and unsubstituted, branched or unbranched; with the proviso that 3 or 4 of the radicals R<sup>9</sup> to R<sup>13</sup> must correspond to H; or

R<sup>12</sup> and R<sup>11</sup> form a 3,4-OCH=CH ring, or

if R<sup>9</sup>, R<sup>11</sup> and R<sup>13</sup> correspond to H, one of R<sup>10</sup> or R<sup>12</sup> also corresponds to H while the other is chosen from the group consisting of Cl, F, OH, CF<sub>2</sub>H, CF<sub>3</sub>, OR<sup>14</sup> and SR<sup>14</sup>, or

if R<sup>9</sup> and R<sup>13</sup> correspond to H, and R<sup>11</sup> corresponds to OH, OCH<sub>3</sub>, Cl or F, one of R<sup>10</sup> or R<sup>12</sup> also corresponds to H while the other corresponds to OH, OCH<sub>3</sub>, Cl or F, or

if R<sup>9</sup>, R<sup>10</sup>, R<sup>12</sup> and R<sup>13</sup> correspond to H, R<sup>11</sup> is chosen from CF<sub>3</sub>, CF<sub>2</sub>H, Cl or F, or

if R<sup>10</sup>, R<sup>11</sup> and R<sup>12</sup> correspond to H, one of R<sup>9</sup> or R<sup>13</sup> also corresponds to H while the other is chosen from the group consisting of OH, OC<sub>2</sub>H<sub>5</sub> and OC<sub>3</sub>H<sub>7</sub>.

49. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein X is chosen from the group consisting of OH, F, OC(O)CH<sub>3</sub> and H.

50. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein R<sup>1</sup> is CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, C<sub>4</sub>H<sub>9</sub> or t-butyl.

51. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein R<sup>2</sup> and R<sup>3</sup> independently of one another are chosen from the group consisting of H, CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, i-propyl and t-butyl.


52. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein R<sup>2</sup> and R<sup>3</sup> together form a C<sub>5-6</sub>-cycloalkyl radical which is saturated and unsubstituted.

53. (previously presented) The composition of matter of claim 52, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein R<sup>2</sup> and R<sup>3</sup> together form a cyclohexyl group.

54. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein R<sup>9</sup> to R<sup>13</sup> independently of one another are chosen from the group consisting of H, Cl, F, OH, CF<sub>2</sub>H, CF<sub>3</sub>, OCH<sub>3</sub>

and SCH<sub>3</sub>; with the proviso that 3 or 4 of the radicals R<sup>9</sup> to R<sup>13</sup> must correspond to H.

55. (previously presented) The composition of matter of claim 48, wherein compounds corresponding to formula I where R<sup>3</sup> = H are in the form of diastereomers corresponding to formula Ia



and are provided in mixtures with a higher content of this diastereomer compared with the other diastereomer<sub>1</sub> or are provided as a pure diastereomer<sub>1</sub> or compounds corresponding to formula I are provided in the form of the (+)-enantiomer.

56. (previously presented) The composition of matter of claim 48, wherein compounds corresponding to formula I, are provided in mixtures with a higher content of the (+)-enantiomer compared with the (-)-enantiomer of a racemic compound or are provided as the pure (+)-enantiomer.

57. (previously presented) The composition of matter of claim 48, wherein said at least one compound selected from group (i) is selected from the group consisting of:

- (2RS,3RS)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol
- (2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol,
- (+)-(2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol,
- (2RS,3RS)-3-(3,4-dichlorophenyl)-1-dimethylamino-2-methyl-pentan-3-ol,

- (2RS,3RS)-3-(3-difluoromethyl-phenyl)-1-dimethylamino-2-methyl-pentan-3-ol,
  - (2RS,3RS)-1-dimethylamino-2-methyl-3-(3-methylsulfanyl-phenyl)-pentan-3-ol,
  - (3RS)-1-dimethylamino-3-(3-methoxy-phenyl)-4,4-dimethyl-pentan-3-ol,
  - (2RS,3RS)-3-(3-dimethylamino-1-ethyl-1-hydroxy-2-methyl-propyl)-phenol,
  - (1RS,2RS)-3-(3-dimethylamino-1-hydroxy-1,2-dimethyl-propyl)-phenol,
  - (+)-(1R,2R)-3-(3-dimethylamino-1-hydroxy-1,2-dimethyl-propyl)-phenol,
  - (+)-(1R,2R)-3-(3-dimethylamino-1-hydroxy-1,2-dimethyl-propyl)-phenol,
  - (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
  - (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
  - (1S,2S)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
  - (+)-(1S,2S)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
  - (+)-(1R,2R)-acetic acid 3-dimethylamino-1-ethyl-1-(3-methoxy-phenyl)-2-methyl-propyl ester,
  - (1RS)-1-(1-dimethylaminomethyl-cyclohexyl)-1-(3-methoxy-phenyl)-propan-1-ol,
  - (2RS,3RS)-3-(4-chlorophenyl)-1-dimethylamino-2-methyl-pentan-3-ol,
  - (+)-(2R,3R)-3-(3-dimethylamino-1-ethyl-1-hydroxy-2-methyl-propyl)-phenol,
  - (2RS,3RS)-4-dimethylamino-2-(3-methoxy-phenyl)-3-methyl-butan-2-ol, and
  - (+)-(2R,3R)-4-dimethylamino-2-(3-methoxy-phenyl)-3-methyl-butan-2-ol,
- and hydrochloride salts of the foregoing.

58. (previously presented) The composition of matter of claim 37, wherein one or more of said at least one compound selected from group (i) is selected from the compounds corresponding to formula II wherein:

X is chosen from the group consisting of OH, F, Cl, OC(O)CH<sub>3</sub> and H,

R<sup>1</sup> is C<sub>1-4</sub>-alkyl, CF<sub>3</sub>, OH, O-C<sub>1-4</sub>-alkyl, Cl or F,

R<sup>9</sup> to R<sup>13</sup> independently of one another are chosen from the group consisting of H, Cl, F, OH, CF<sub>2</sub>H, CF<sub>3</sub> and C<sub>1-4</sub>-alkyl, saturated and unsubstituted, branched

or unbranched; OR<sup>14</sup> or SR<sup>14</sup>, where R<sup>14</sup> is chosen from C<sub>1-3</sub>-alkyl, saturated and unsubstituted, branched or unbranched; with the proviso that 3 or 4 of the radicals R<sup>9</sup> to R<sup>13</sup> must correspond to H; or

R<sup>12</sup> and R<sup>11</sup> form a 3,4-OCH=CH ring, or

if R<sup>9</sup>, R<sup>11</sup> and R<sup>13</sup> correspond to H, one of R<sup>10</sup> or R<sup>12</sup> also corresponds to H while the other is chosen from the group consisting of Cl, F, OH, CF<sub>2</sub>H, CF<sub>3</sub>, OR<sup>14</sup> and SR<sup>14</sup>, or

if R<sup>9</sup> and R<sup>13</sup> correspond to H, and R<sup>11</sup> corresponds to OH, OCH<sub>3</sub>, Cl or F, one of R<sup>10</sup> or R<sup>12</sup> also corresponds to H while the other corresponds to OH, OCH<sub>3</sub>, Cl or F, or

if R<sup>9</sup>, R<sup>10</sup>, R<sup>12</sup> and R<sup>13</sup> correspond to H, R<sup>11</sup> is CF<sub>3</sub>, CF<sub>2</sub>H, Cl or F, or

if R<sup>10</sup>, R<sup>11</sup> and R<sup>12</sup> correspond to H, one of R<sup>9</sup> or R<sup>13</sup> also corresponds to H while the other is OH, OC<sub>2</sub>H<sub>5</sub> or OC<sub>3</sub>H<sub>7</sub>.

59. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula II wherein X is OH, F or H.


60. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula II wherein R<sup>1</sup> is OH, CF<sub>3</sub> or CH<sub>3</sub>.

61. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula II wherein:

R<sup>9</sup> to R<sup>13</sup> independently of one another are chosen from the group consisting of H, Cl, F, OH, CF<sub>2</sub>H, CF<sub>3</sub>, OCH<sub>3</sub> and SCH<sub>3</sub>, with the proviso that 3 or 4 of the radicals R<sup>9</sup> to R<sup>13</sup> must correspond to H, or

if R<sup>9</sup>, R<sup>11</sup> and R<sup>13</sup> correspond to H, one of R<sup>10</sup> or R<sup>12</sup> also corresponds to H while the other is OH, CF<sub>2</sub>H, OR<sup>14</sup> or SCH<sub>3</sub>.

62. (previously presented) The composition of matter of claim 58, wherein the compounds corresponding to formula II are in the form of diastereomers corresponding to formula IIa



IIa

and are provided in mixtures with a higher content of this diastereomer compared with the other diastereomer<sub>2</sub> or are provided as a pure diastereomer, or compounds corresponding to formula II are provided in the form of the (+)-enantiomer.

63. (previously presented) The composition of matter of claim 58, wherein compounds corresponding to formula II are provided in mixtures with a higher content of the (+)-enantiomer compared with the (-)-enantiomer of a racemic compound or are provided in the form of the pure (+)-enantiomer.

64. (previously presented) The composition of matter of claim 58, wherein said at least one compound selected from group (i) is selected from the group consisting of:

- (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol,
- (+)-(1R,3R,6R)-6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol,

- (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol,
- (1RS,3SR,6RS)-6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol,
- (+)-(1R,2R,5S)-3-(2-dimethylaminomethyl-1-hydroxy-5-methyl-cyclohexyl)-phenol, and
- (1RS,2RS,5RS)-3-(2-dimethylaminomethyl-1-hydroxy-5-trifluoromethyl-cyclohexyl)-phenol,

and hydrochloride salts of the foregoing.

65. (previously presented) The composition of matter of claim 37, wherein one or more of said at least one compound selected from group (i) is selected from the compounds corresponding to formula III wherein:

X is chosen from the group consisting of OH, F, Cl, OC(O)CH<sub>3</sub> and H,

R<sup>9</sup> to R<sup>13</sup> independently of one another are chosen from the group consisting of H, Cl, F, OH, CF<sub>2</sub>H, CF<sub>3</sub>, C<sub>1-4</sub>-alkyl, saturated and unsubstituted, branched or unbranched; OR<sup>14</sup> and SR<sup>14</sup>, where R<sup>14</sup> is chosen from C<sub>1-3</sub>-alkyl, saturated and unsubstituted, branched or unbranched; with the proviso that 3 or 4 of the radicals R<sup>9</sup> to R<sup>13</sup> must correspond to H; or

R<sup>12</sup> and R<sup>11</sup> form a 3,4-OCH=CH ring, or

if R<sup>9</sup>, R<sup>11</sup> and R<sup>13</sup> correspond to H, one of R<sup>10</sup> or R<sup>12</sup> also corresponds to H while the other is Cl, F, OH, SH, CF<sub>2</sub>H, CF<sub>3</sub>, OR<sup>14</sup> or SR<sup>14</sup>, or

if R<sup>9</sup> and R<sup>13</sup> correspond to H and R<sup>11</sup> corresponds to OH, OCH<sub>3</sub>, Cl or F, one of R<sup>10</sup> or R<sup>12</sup> also corresponds to H while the other corresponds to OH, OCH<sub>3</sub>, Cl or F, or

if R<sup>9</sup>, R<sup>10</sup>, R<sup>12</sup> and R<sup>13</sup> correspond to H, R<sup>11</sup> is CF<sub>3</sub>, CF<sub>2</sub>H, Cl or F, or


if R<sup>10</sup>, R<sup>11</sup> and R<sup>12</sup> correspond to H, one of R<sup>9</sup> or R<sup>13</sup> also corresponds to H while the other is OH, OC<sub>2</sub>H<sub>5</sub> or OC<sub>3</sub>H<sub>7</sub>.

66. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula III wherein X is OH, F or H.

67. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula III wherein:

R<sup>9</sup> to R<sup>13</sup> independently of one another are chosen from the group consisting of H, Cl, F, OH, CF<sub>2</sub>H, CF<sub>3</sub>, OCH<sub>3</sub> and SCH<sub>3</sub>, with the proviso that 3 or 4 of the radicals R<sup>9</sup> to R<sup>13</sup> must correspond to H; or  
if R<sup>9</sup>, R<sup>11</sup> and R<sup>13</sup> correspond to H, one of R<sup>10</sup> or R<sup>12</sup> also corresponds to H while the other is OH, CF<sub>2</sub>H, OR<sup>14</sup> or SCH<sub>3</sub>.

68. (previously presented) The composition of matter of claim 65, wherein the compounds corresponding to formula III are in the form of diastereomers corresponding to formula IIIa



IIIa

and are provided in mixtures with a higher content of this diastereomer compared with the other diastereomer<sub>1</sub> or are provided as a pure diastereomer, or compounds corresponding to formula III are provided in the form of the (+)-enantiomer.



69. (previously presented) The composition of matter of claim 65, wherein compounds corresponding to formula III, are provided in mixtures with a higher content of the (+)-enantiomer compared with the (-)-enantiomer of a racemic compound or are provided in the form of the pure (+)-enantiomer.

70. (previously presented) The composition of matter of claim 65, wherein said at least one compound selected from group (i) is selected from the group consisting of:

- (+)-(1R,2R)-3-(2-dimethylaminomethyl-1-fluoro-cyclohexyl)-phenol,
  - (+)-(1S,2S)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol or
  - (1S,2S)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol or
  - (-)-(1R,2R)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol,
  - (1R,2R)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol,
  - (-)-(1R,2R)-[2-(3-methoxy-phenyl)-cyclohexylmethyl]-dimethylamine, and
  - (1R,2R)-[2-(3-methoxy-phenyl)-cyclohexylmethyl]-dimethylamine,
- and hydrochloride salts of the foregoing.

71. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (ii) is selected from the group consisting of: darifenacin, duloxetine, oxybutinin and tolterodine.

72. (previously presented) The composition of matter of claim 37, wherein said at least one compound selected from group (ii) is selected from the group consisting of: oxybutinin and tolterodine.

73. (previously presented) A pharmaceutical formulation comprising as an active compound combination a composition of matter according to claim 37 and at least one pharmaceutically suitable additive or auxiliary substance.